News | August 13, 2025
Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
US business grew by +12.8% YoY
The inspection was conducted at its Goa, Vema manufacturing facility
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
Subscribe To Our Newsletter & Stay Updated
